Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Ref Type | |||||||||||||
| PMID | (41721087) | ||||||||||||
| Authors | Shoumariyeh K, Haug S, Schwaab J, Pfeil JK, Stappenbeck J, Schmitt-Graeff A, Naumann N, Waltemode G, Zeiser R, Miething C, Hofmann WK, Meggendorfer M, Diederichs S, Duyster J, Reiter A | ||||||||||||
| Title | The FGFR1 N546K mutation confers resistance to pemigatinib in MLN-ZMYM2::FGFR1. | ||||||||||||
|
|||||||||||||
| URL | |||||||||||||
| Abstract Text | |||||||||||||
| Molecular Profile | Treatment Approach |
|---|
| Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
|---|
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|
| Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
|---|
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| FGFR1 N546K | lung cancer | resistant | Pemigatinib | Preclinical - Cell culture | Actionable | In a preclinical study, a lung cancer cell line expressing FGFR1 N546K was resistant to Pemazyre (pemigatinib) treatment in culture (PMID: 41721087). | 41721087 |
| FGFR1 N546K | lung cancer | resistant | Futibatinib | Preclinical - Cell culture | Actionable | In a preclinical study, Lytgobi (futibatinib) inhibited viability of a lung cancer cell line expressing FGFR1 N546K in culture (PMID: 41721087). | 41721087 |
| FGFR1 N546K | lung cancer | resistant | Fexagratinib | Preclinical - Cell culture | Actionable | In a preclinical study, a lung cancer cell line expressing FGFR1 N546K was resistant to Fexagratinib (AZD4547) treatment in culture (PMID: 41721087). | 41721087 |
| FGFR1 N546K | lung cancer | sensitive | Tinengotinib | Preclinical - Cell culture | Actionable | In a preclinical study, Tinengotinib (TT-00420) inhibited viability of a lung cancer cell line expressing FGFR1 N546K in culture (PMID: 41721087). | 41721087 |